MYOC and lung adenocarcinoma: For example, MYOC mutations that were determined to be stabilizing have been found in prostate neuroendocrine, cervical squamous cell, uterine endometrioid, bladder urothelial, and lung squamous cell carcinomas; colon, endocervical, colorectal, prostate, and lung adenocarcinomas; and acral and desmoplastic melanomas, uterine carcinosarcoma, anaplastic astrocytoma, and diffuse glioma [39,40].